NVS - Kala Pharmaceuticals Looks To Keep Rally Going
Today, we will see why Kala Pharmaceuticals (KALA) is an attractive pick in March 2020. Despite the massive selloff across markets due to coronavirus pandemic, the company has managed to post around 100% return on YTD (year-to-date) basis.
Company overview
Headquartered in Watertown, Massachusetts, Kala Pharmaceuticals is a biopharmaceutical company focused on leveraging its proprietary nanoparticle-based MPP (Mucus Penetrating Particles) technology for treating eye diseases. The company was founded in 2009 and went public in 2017.
The MPPs are made of selectively-sized nanoparticles with proprietary coatings. These attributes are expected to ensure even